The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer |
| |
| Authors: | Ming-Gao Guo Qi Zheng Zhe Cheng Yu Wang Chang-Ning Feng Zhe Yang |
| |
| Affiliation: | 1. Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People''s Hospital, Shanghai 200233, China;2. Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People''s Hospital, Shanghai 200233, China;1. Oncology Institute, Shaare Zedek Medical Centre, Jerusalem, Israel;2. Section of GI and Lymphoma Units, Department of Medicine, The Royal Marsden Hospital, London;3. Clinical Research and Development, The Royal Marsden NHS Foundation Trust, London;4. Department of Oncology, UCL Cancer Institute, London, UK |
| |
| Abstract: | The prognosis of local advanced gastric carcinoma is very poor. We evaluated the impact on survival and the effects induced by the triple combination docetaxel–cisplatin–fluorouracil (DCF) as neoadjuvant chemotherapy in 24 T4 stage gastric tumor patients. They received 2–3 cycles DCF chemotherapy, followed by radical gastric resection. Tumor downstaging detected by CT was obtained in 17 out of 24 patients. The overall 3-year survival rate was 68.2%. Patients who received R0 resection (19/22) showed a 3-year survival rate of 78.9%. T downstaged patients (17/22) showed a higher 3-year survival rate of 82.4%. Those who responded to the triple combination of docetaxel–cisplatin–fluorouracil, exhibited T downstaging and subsequently received an R0 resection had a definitely better chance of a cure as compared to surgery alone, according to a complete 3-year follow-up. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
